A new trial shows adding Keytruda (pembrolizumab) to chemotherapy consistently reduces and sustains the size of tumours in patients with metastatic non-small cell lung cancer (NSCLC).

Researchers say the addition of Keytruda (pembrolizumab) almost doubled the overall response rate of chemo for patients with untreated metastatic squamous NSCLC.

Find out more in this Immuno Oncology News article.